This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Could virtual reality tools be effective in helping patients ‘unlearn’ their chronic pain? p harmaphorum speaks to Professor Christopher Eccleston from the University of Bath’s Centre of Pain Research to find out how digital therapeutics are shaping the future of pain management. A digital software developed by Finnish drugmaker Orion is aiming to address chronic pain conditions using virtual reality (VR) devices that provide an immersive gamified therapeutic treatment program.
A recent survey conducted by dosing technology firm found that the vast majority (85%) of patients think that personalized medicine stands to improve care.
Immunotherapy and Tyrosine Kinase Inhibitor Combination Approved for the Treatment of Patients With Advanced Endometrial Carcinoma Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma TOKYO and KENILWORTH, N.J. – (JCN Newswire) – Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Oliver Stohlmann’s new Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. In this first instalment he tackles managing time. A month into exiting my career of over two decades in global life-science multinationals, I’m alive – still, but waiting for withdrawal symptoms to kick in.
SOMERSET, N.J. — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.
Pfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from its protein degrader platform, which harnesses cells’ natural protein-denaturing machinery to remove rogue proteins associated with disease. The deal focuses on ARV-471, currently in phase 2 testing for advanced breast cancer patients whose tumours expresses oestrogen receptors – so are hormone sensitive – but test negative for HER2 receptors that would make them candidates for treatment w
The World Health Organization hopes to encourage the development of novel therapies for tuberculosis by spotlighting key clinical study characteristics.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
On 9 November 2021, the 18th Annual CPhI Pharma Awards will take place in Milan, Italy at the Stella Polare Convention Centre. The CPhI Pharma Awards celebrate innovators and thought leaders breaking new ground in the pharma and biopharma industries, and their commitment to advancing new approaches, processes and technologies. Held as part of CPhI Worldwide (9-11 November 2021), the world’s largest pharma exhibition, these prestigious awards recognise the individuals, teams and companies who tur
Think of the R&D dollars that could be saved if artificial intelligence (AI) modelling could tell you at an early stage whether a drug was likely to succeed in clinical trials, and ultimately reach the market. In 2019, a team at Massachusetts Institute of Technology (MIT) in the US came up with just such a model, and found that it was able to perform “better than random” at predicting the outcome of a clinical trial or development programme.
This monthâs roundup of new excipients, manufacturing sites, partnerships, and other items includes news from DFE Pharma, Vetter, and other notable firms.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
At the PMN Summer Summit of 2021, leaders from an array of disciplines and roles within the industry came together to discuss the all-important concept of Customer Experience, and specifically, how CX continues to evolve in the aftermath of the global pandemic crisis, COVID-19. The summit consisted of three panel discussions: “Coordinated CX: Moving Beyond Campaign Management,” “Digital Customer Experience and Analytics,” and “The Engagement Matrix: A Holistic View of CX.
EPG Health’s Allen Wellings assesses future symposia and congress models, outlining some learnings about content and reach. COVID-19 had a huge, and very obvious, initial impact on medical congresses and symposia when 2020’s lockdowns took effect, with many events struggling to move quickly enough to a purely digital format. While many did succeed in creating digital learning environments during those difficult early months of the pandemic, there are some clear learnings for pharma companies in
The health data specialist and pharma firm are partnering on solutions around remote collection of digital data for detection and monitoring of treatments.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
At the PMN Summer Summit of 2021, leaders from an array of disciplines and roles within the industry came together to discuss the all-important concept of Customer Experience, and specifically, how CX continues to evolve in the aftermath of the global pandemic crisis, COVID-19. The summit consisted of three panel discussions: “Coordinated CX: Moving Beyond Campaign Management,” “Digital Customer Experience and Analytics,” and “The Engagement Matrix: A Holistic View of CX.
Happify Health has launched a prescription digital therapeutic (DTx) – called Ensemble – that can assist the treatment of people with both major depressive disorder and generalised anxiety disorder in the US market. The 10-week smartphone or PC based programme is the first and only prescription DTx for both indications, which according to the digital health company often together in around 20% of patients with MDD in a 12-month period.
A leader from the artificial intelligence solutions firm discusses how advanced analytical tools can help researchers make the most of mountains of data.
Confused Drug Names, Formerly Known as Look-Alike Sound-Alike (LASA) Medications For many years, the Institute for Safe Medication Practices (ISMP), has acknowledged that similar medication names, brand or generic, pose a real risk of medication errors in any healthcare setting. Recently, the nomenclature of Look-Alike Sound-Alike (LASA) medications were changed to Confused Drug Names.
The FDA has taken a longer than usual look at Ardelyx’ regulatory submission for tenapanor, a drug for high blood phosphate levels associated with chronic kidney disease (CKD), and found it wanting – sending the biotech’s shares into a tailspin. The US regulator had extended its review of the drug by three months – setting back its action date from April to 29 July – but now says that deficiencies in the marketing application “preclude discussion” of labelling and post-ma
Putting Spirit Back in Psychiatry. The word root 'psyche' can be translated to the human mind, soul, or spirit. Therefore, psychiatry is literally a field of medicine that is inherently about healing the spirit. Yet, in our current day and age the biological paradigm of mental health has led most to forget this. Instead of talking about what a person needs to feel happy, fulfilled, aligned, connected, valued, and like the most authentic version of themselves in psychiatry, the focus is on 'neuro
The process management solutions firm says drug companies could use contract data to get a better handle on predicting demand and adjusting product output.
The EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started a 35,000-patient phase 3 trial in May. The vaccine – now dubbed Vidprevtyn – is based on a recombinant protein antigen developed by Sanofi’s vaccines unit Sanofi Pasteur, and also includes an immune-boosting adjuvant developed by GSK that aims to boost its efficacy.
Phosphodiesterase-5 inhibitors, or PDE-5 inhibitors, are often the first-line therapy for erectile dysfunction. PDE-5 inhibitors do not produce an erection in the absence of stimulation – rather they enhance the effect of nitric oxide by inhibiting PDE-5-mediated hydrolysis of cGMP, which is present during stimulation. Below we provide a comparison of PDE-5 Inhibitors.
A recent study indicates patients taking the cholesterol-lowering drugs prior to COVID hospitalization are far less likely to die as a result of the virus.
Digital therapeutics (DTx) startup Dopavision has raised funding to develop its lead product, an app designed to slow the progression of myopia – or short-sightedness – in children or adolescents. The €12 million series round, led by Seventure Partners and backed by investors including Novartis, Boehringer Ingelheim and Abbax Health, will be used to fund clinical development of the DTx.
Last week, the FDA approved finerenone (Kerendia) to treat patients with chronic kidney disease (CKD) associated with type 2 diabetes. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA). The approval of finerenone was due to the results of the recently completed FIDELIO-DKD trial, which demonstrated the protective effects of finerenone.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
145 
Let's personalize your content